MedTrace Logo

Efficacy Evaluation of UCB-MNCs in the Treatment of Refractory Neonatal Diseases

NCT06427642 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2024-05-24

No results posted yet for this study

Summary

Hypoxic-ischemic encephalopathy (HIE), bronchopulmonary dysplasia (BPD), short bowel syndrome (SBS) are refractory in clinical treatment. Thus, how to better prevent such diseases is currently a key research topic in the international field. The use of cord blood-derived mononuclear cells may promote to save lives and improve patient outcomes.

Conditions

  • Hypoxic-Ischemic Encephalopathy
  • Bronchopulmonary Dysplasia
  • Short Bowel Syndrome

Interventions

BIOLOGICAL

Mononuclear cells

UCB-MNCs are obtained from umbilical cord blood by density gradient centrifugation

DEVICE

Mild hypothermia therapy

Mild hypothermia therapy via hypothermia therapy apparatus

DEVICE

Breathing support technique

Breathing support via ventilator

PROCEDURE

Total parenteral nutrition

Liquid nutrition injected directly into the bloodstream

Sponsors & Collaborators

  • Qilu Children's Hospital of Shandong University

    collaborator OTHER

  • Shandong Qilu Stem Cells Engineering Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Xiaoying Li, MD · Qilu Children's Hospital of Shandong University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
1 Day
Max Age
28 Days
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-04-01
Primary Completion
2024-05-30
Completion
2025-04-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06427642 on ClinicalTrials.gov